title: Efficacy of recombinant gamma interferon for treatment of systemic cryptococcosis in SCID mice.
abstract: We have previously shown that gamma interferon (IFN-gamma) is a useful adjunct to therapy of experimental systemic cryptococcosis in normal mice. To better emulate AIDS patients, SCID mice were infected intravenously with Cryptococcus neoformans. Mice received no therapy, 3 mg of amphotericin B (AmB) per kg of body weight, or 10(5) U of IFN-gamma alone (prophylactically and therapeutically or only therapeutically) or with AmB. In the first experiment, >75% of the mice survived. Therapy with AmB alone was efficacious compared to no therapy in all organs. Both regimens of IFN-gamma alone were efficacious in the brain and lungs, and the combination of AmB and IFN-gamma showed significant synergy in the kidneys. AmB alone cured 40% of mice of infection, whereas the combination regimens cured >50% of the mice and 90% of the brain infections. In a second study, IFN-gamma again proved efficacious alone, and when given with AmB its efficacy was improved. Therapeutic IFN-gamma alone was effective only in the liver compared to no therapy, and the combination regimen, although highly effective, showed no significant synergy. In a third experiment, AmB alone or in combination with IFN-gamma prolonged survival compared to no therapy or IFN-gamma alone. The combination regimen showed significant synergy over AmB alone in the brain, liver, kidneys, and lungs. AmB alone cured no mice of infections in more than two organs, whereas AmB in combination with IFN-gamma cured 55% of infections in three or more organs. These results indicate that IFN-gamma has therapeutic efficacy in severely immunodeficient animals, especially in combination with AmB. Significant synergistic activity was noted in all organs except the spleen. Overall, IFN-gamma has utility as an adjunctive therapy against systemic cryptococcosis in the severely immunocompromised host.
authors.affiliation: Department of Medicine, Division of Infectious Diseases, Santa Clara Valley Medical Center, San Jose, California 95128, USA. Karl.Clemons@slip.net
authors.forename: K V
authors.initials: KV
authors.lastname: Clemons
authors.forename: J E
authors.initials: JE
authors.lastname: Lutz
authors.forename: D A
authors.initials: DA
authors.lastname: Stevens
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000666:Amphotericin B / Q000627:therapeutic use; D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use; D003453:Cryptococcosis / Q000188:drug therapy* / Q000276:immunology; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D007371:Interferon-gamma / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D016513:Mice, SCID; D011994:Recombinant Proteins / Q000494:pharmacology; D016896:Treatment Outcome
chemical_list: D000276:Adjuvants, Immunologic; D000935:Antifungal Agents; D011994:Recombinant Proteins; D000666:Amphotericin B; D007371:Interferon-gamma